Why are pediatric PK dosing regimens often based on weight or body surface area, and what PK principles underlie this practice?

Why are pediatric PK dosing regimens often based on weight or body surface area, and what PK principles underlie this practice?

• A. Maturation and growth alter clearance and distribution; allometric scaling and maturation functions are used.
• B. Children metabolize drugs identically to adults.
• C. Weight-based dosing is arbitrary.
• D. Pediatric PK relies only on fixed mg/kg without scaling.

Answer: (A)

Growth and maturation change how drugs are absorbed, distributed, metabolized, and excreted in children. Because kids differ from adults in size and in the maturation of their organs, PK parameters like clearance and volume of distribution are not the same across ages and weights. Allometric scaling uses body size (usually weight) to relate PK between individuals, recognizing that many physiological processes scale nonlinearly with weight. In addition, maturation functions account for ontogeny—the gradual development of organs and enzyme systems that govern drug metabolism and renal excretion. Together, these approaches help predict how a given dose will translate into drug exposure (such as AUC) in a child compared with an adult, guiding dosing by weight or body surface area to achieve similar therapeutic levels. That’s why simply saying children metabolize drugs the same as adults is incorrect; enzyme activity and renal function change with age. And fixed mg/kg dosing or using weight alone without scaling can miss differences in maturation and organ size, leading to under- or over-exposure. While mg/kg is a common starting point, incorporating allometric scaling with maturation adjustments provides a more accurate framework for pediatric dosing.

Growth and maturation change how drugs are absorbed, distributed, metabolized, and excreted in children. Because kids differ from adults in size and in the maturation of their organs, PK parameters like clearance and volume of distribution are not the same across ages and weights. Allometric scaling uses body size (usually weight) to relate PK between individuals, recognizing that many physiological processes scale nonlinearly with weight. In addition, maturation functions account for ontogeny—the gradual development of organs and enzyme systems that govern drug metabolism and renal excretion. Together, these approaches help predict how a given dose will translate into drug exposure (such as AUC) in a child compared with an adult, guiding dosing by weight or body surface area to achieve similar therapeutic levels.

That’s why simply saying children metabolize drugs the same as adults is incorrect; enzyme activity and renal function change with age. And fixed mg/kg dosing or using weight alone without scaling can miss differences in maturation and organ size, leading to under- or over-exposure. While mg/kg is a common starting point, incorporating allometric scaling with maturation adjustments provides a more accurate framework for pediatric dosing.